Infections due to Non-fermenting Gram-negative Bacilli

Definition/Significance

NFGNB = Gram-negative rods, DON’T FERMENT GLUCOSE (oxidative or non-metabolizing) — distinguishes from fermentative Enterobacteriaceae. Disproportionately: ENVIRONMENTAL organisms (water, soil, moist hospital surfaces), affect HOSPITALIZED/critically ill/structural lung disease patients, MDR-prone.

Pseudomonas aeruginosa

Motile, oxidase-POSITIVE, aerobic. Minimal nutritional needs, remarkable environmental hardiness (survives/multiplies in moist hospital environments — humidifiers, vent tubing, sinks, even dilute disinfectant). PYOCYANIN (blue-green pigment, species name source) + PYOVERDINE (fluorescent green siderophore) — ID clues.

Risk groups/clinical:

• Cystic fibrosis: chronic colonization essentially UNIVERSAL by adulthood, major lung decline/mortality driver. MUCOID PHENOTYPE develops over years (alginate overproduction, biofilm — entrenches persistence/resistance)
• Ventilated ICU: leading VAP cause (see HAI topic)
• Bronchiectasis/severe COPD: structurally damaged airway = chronic colonization niche
• Neutropenic/immunocompromised: high-mortality bacteremia, specific febrile neutropenia empirical coverage target

AMR: combines INTRINSIC resistance (low-permeability outer membrane, constitutive efflux pumps) + strong ACQUIRED resistance propensity (mutation/HGT, even during single treatment course). Genuinely difficult-to-treat. Antipseudomonal-specific agents: pip-tazo, ceftazidime, cefepime, carbapenems, aminoglycosides, antipseudomonal fluoroquinolones (ciprofloxacin).

Acinetobacter baumannii

Notorious healthcare pathogen. Environmental hardiness — SURVIVES DRY SURFACES for WEEKS (unusual, most Gram-negatives can’t) — persistent outbreak source via contaminated equipment/surfaces even post-cleaning. Affects: ICU, ventilated, extensive antibiotic exposure patients.

Defining significance: EXTENSIVE RAPIDLY ACQUIRED MDR. Carbapenem-resistant Acinetobacter = WHO-PRIORITIZED CRITICAL THREAT pathogen. Often leaves COLISTIN (older toxic polymyxin, see AMR topic, brought back specifically for this crisis) as one of few reliable options.

Burkholderia cepacia Complex

Narrow but important niche: CYSTIC FIBROSIS patients. Colonization = disproportionate significance — subset develop “CEPACIA SYNDROME” (accelerated/fulminant lung decline). CF centers: STRICT COHORTING/segregation of cepacia+ from cepacia- patients (clinic + inpatient) to prevent cross-transmission — distinctive infection-control practice specific to this organism/population.

Laboratory Diagnosis (General)

Culture + oxidase test: Pseudomonas = POSITIVE, Acinetobacter = NEGATIVE (quick discriminator between the 2 most important members). MALDI-TOF/VITEK further ID. AST ESSENTIALLY MANDATORY for any clinically significant NFGNB isolate — empirical Rx by organism ID alone LESS RELIABLE here than most other bacterial groups (unpredictable resistance even within species).

Treatment Principles

Susceptibility-GUIDED, not fixed algorithm. Empirical (at-risk patient: known colonization, structural lung disease, ICU/vent) = BROAD start (antipseudomonal beta-lactam ± aminoglycoside/fluoroquinolone synergy) → NARROW per susceptibility (de-escalation, see Bacteremia/Sepsis topic). Source control (device removal/exchange, address structural lung problem) matters alongside antibiotics — same “antibiotics alone often insufficient” pattern as osteomyelitis, gas gangrene, CDI (persistent reservoir/biofilm).

What “Non-fermenting” Means and Why It Matters

Non-fermenting Gram-negative bacilli (NFGNB) are a biochemically defined group — Gram-negative rods that do not ferment glucose (deriving energy oxidatively instead, or not metabolizing it at all), distinguishing them from the fermentative Enterobacteriaceae (E. coli, Klebsiella, and the other organisms covered under Bacteremia/Sepsis and the GI topics) that dominate most other Gram-negative infection discussions in this curriculum. This single biochemical distinction carries real clinical weight: NFGNB as a group are disproportionately environmental organisms (found in water, soil, and moist hospital surfaces/equipment) rather than gut commensals, disproportionately affect hospitalized, critically ill, or structurally-lung-diseased patients rather than otherwise healthy individuals, and are disproportionately associated with intrinsic and acquired multidrug resistance, making them a genuinely important and growing healthcare-associated infection problem covered here specifically in their respiratory disease role. Pseudomonas aeruginosa is covered in the most depth given its clinical dominance within this group; Acinetobacter baumannii and Burkholderia species (B. pseudomallei, causing melioidosis, covered under its own topic; B. cepacia, mentioned here) round out the clinically important members.

Pseudomonas aeruginosa

The Organism

A motile, oxidase-positive, aerobic Gram-negative rod, genuinely notable for minimal nutritional requirements and remarkable environmental hardiness — it survives and even multiplies in moist hospital environments (humidifiers, ventilator tubing, sinks, disinfectant solutions themselves if inadequately concentrated) that would not support most other bacteria, which is exactly why it is such a persistent, difficult-to-eradicate healthcare-associated pathogen. It characteristically produces a distinctive blue-green pyocyanin pigment (the source of its species name and the classic, grape-like/corn-tortilla odour some strains produce on culture) and a fluorescent green pyoverdine siderophore, both genuinely useful bedside/laboratory identification clues.

Risk Factors and Clinical Manifestations

Pseudomonas respiratory infection concentrates heavily in specific vulnerable populations, and recognizing these risk groups is itself diagnostically useful: cystic fibrosis patients, where chronic Pseudomonas colonization/infection is essentially universal by adulthood and a major determinant of long-term lung function decline and mortality, with the organism adapting over years of chronic infection into a distinctive mucoid phenotype (overproducing alginate, forming a protective biofilm that further entrenches its persistence and resistance to both host defences and antibiotics); ventilated ICU patients, where it is a leading cause of ventilator-associated pneumonia (see Hospital Acquired Infections); bronchiectasis and severe COPD patients, whose structurally damaged airways provide the same kind of chronically colonizable niche seen in cystic fibrosis; and neutropenic/immunocompromised patients, where Pseudomonas bacteraemia carries a particularly high mortality and is a specific target of the empirical antibiotic coverage used in febrile neutropenia.

Antimicrobial Resistance

Pseudomonas is genuinely notable for combining intrinsic resistance (a naturally low-permeability outer membrane and constitutively expressed efflux pumps limiting many antibiotics from the start) with a strong propensity for acquiring further resistance during treatment (via mutation or horizontal gene transfer, sometimes emerging over the course of a single treatment course) — a combination that makes it one of the more genuinely difficult-to-treat organisms covered across this curriculum, and why antipseudomonal-specific agents (piperacillin-tazobactam, ceftazidime, cefepime, carbapenems, aminoglycosides, and antipseudomonal fluoroquinolones like ciprofloxacin) form their own recognized category distinct from standard empirical Gram-negative coverage.

Acinetobacter baumannii

A genuinely notorious healthcare-associated pathogen, sharing Pseudomonas’s environmental hardiness (including, distinctively, an unusual capacity to survive on dry surfaces for extended periods — weeks in some studies — which most other Gram-negative bacteria cannot do, making it a persistent source of outbreak transmission via contaminated equipment and surfaces even after apparent cleaning) and disproportionately affecting ICU patients, ventilated patients, and those with extensive antibiotic exposure. Acinetobacter’s defining current clinical significance is its capacity for extensive, rapidly acquired multidrug resistance, with carbapenem-resistant Acinetobacter now a globally recognized, WHO-prioritized critical-threat pathogen, frequently leaving colistin (a older, more toxic polymyxin-class agent, covered under Antimicrobial Agents and Antimicrobial Resistance, brought back into routine use specifically because of this resistance crisis) as one of few remaining reliably active treatment options.

Burkholderia cepacia Complex

A group of related species, genuinely notable for a specific, narrow but important clinical niche: infection in cystic fibrosis patients, where colonization carries disproportionate significance — a subset of CF patients who acquire B. cepacia complex experience an accelerated, sometimes fulminant decline in lung function (“cepacia syndrome”), and CF centres accordingly practice strict cohorting/segregation of B. cepacia-positive patients from B. cepacia-negative patients to prevent cross-transmission within clinic and inpatient settings — a genuinely distinctive infection-control practice specific to this organism within the CF population.

Laboratory Diagnosis (General, Across This Topic)

Culture on standard media, with oxidase testing (positive for Pseudomonas, negative for Acinetobacter — a genuinely useful, quick discriminator between the two most clinically important members of this group) and further biochemical/automated (MALDI-TOF, VITEK) identification. Given the strong association with intrinsic and acquired resistance across this entire organism group, antimicrobial susceptibility testing is essentially mandatory for any clinically significant NFGNB isolate — empirical treatment based on organism identity alone, without susceptibility data, is genuinely less reliable here than for most other bacterial groups covered in this curriculum, given how unpredictable resistance patterns can be even within a single species.

Treatment Principles

Given the resistance patterns described above, treatment is genuinely susceptibility-guided rather than following a simple fixed algorithm the way, say, GAS pharyngitis treatment does — empirical coverage in a patient at genuine risk (known colonization, structural lung disease, ICU/ventilated setting) typically starts broad (antipseudomonal beta-lactam, sometimes combined with an aminoglycoside or fluoroquinolone for synergy/broader initial coverage while awaiting results), then narrows once susceptibility data return, following the same de-escalation principle covered under Bacteremia, Septicemia and Sepsis. Source control (removing/exchanging a colonized device, addressing an underlying structural lung problem where feasible) matters alongside antibiotic choice, mirroring the same “antibiotics alone often aren’t enough” principle that recurs across several other topics in this curriculum (osteomyelitis, gas gangrene, CDI) wherever a persistent physical reservoir or biofilm is involved.